Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Inflammation01:38

Inflammation

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olezarsen and Plozasiran: Novel apoC-III targeting medications for the treatment of hypertriglyceridemia.

Journal of cardiovascular pharmacology·2026
Same author

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Journal of the American College of Cardiology·2026
Same author

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same author

The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia-Best evidence and practices aligned.

Journal of clinical lipidology·2026
Same author

New Dyslipidemia Guideline Expands Treatment Options and Risk Assessment in Patients With Diabetes and Chronic Kidney Disease.

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: May 11, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Nonstatins for LDL-C lowering: An expansion whose time has come.

Joseph J Saseen1, Dave L Dixon2

  • 1Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy, Aurora, CO, United States (Saseen); Department of Family Medicine, University of Colorado Anschutz Medical Campus School of Medicine, United States (Saseen).

Journal of Clinical Lipidology
|May 9, 2026
PubMed
Summary

New guidelines emphasize combination therapy for lowering low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) to reduce cardiovascular risk. Nonstatin therapies are now core components of care, especially for high-risk patients.

Keywords:
GuidelineLipid goalsNonstatinsPharmacotherapyProprotein convertase subtilisin/kexin type 9 inibitor

Related Experiment Videos

Last Updated: May 11, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

  • Cardiology
  • Lipidology
  • Pharmacotherapy

Background:

  • The 2026 ACC/AHA Dyslipidemia Guideline reinstates LDL-C and non-HDL-C treatment goals.
  • Statin monotherapy is often insufficient for achieving lipid goals, particularly in high-risk or statin-intolerant patients.

Purpose of the Study:

  • To review the expanded role of nonstatin therapies in lipid management.
  • To discuss new outcomes data supporting lower LDL-C targets.
  • To explore the future of LDL-C-lowering therapies.

Main Methods:

  • Review of current guidelines and outcomes data.
  • Analysis of the role of existing nonstatin agents.
  • Exploration of emerging lipid-lowering therapies.

Main Results:

  • Nonstatin therapies are now integral to evidence-based care for dyslipidemia.
  • New data support the "lower is better" principle for LDL-C reduction.
  • Next-generation therapies promise personalized care and improved adherence.

Conclusions:

  • Combination lipid-lowering therapy is essential for achieving optimal LDL-C levels.
  • Achieving and sustaining target lipid levels significantly reduces atherosclerotic cardiovascular disease risk.
  • The evolving landscape of lipid-lowering therapies offers new strategies for individualized patient care.